Cogentin (benztropine) is a small molecule pharmaceutical. Benztropine was first approved as Cogentin on 1982-01-01. It is used to treat drug-induced abnormalities and parkinson disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, sodium-dependent dopamine transporter, and sodium-dependent neutral amino acid transporter B(0)AT1.
|Indication||drug-induced abnormalities, parkinson disease|
|Drug Class||Atropine derivatives|